{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:05:52Z","timestamp":1761491152309,"version":"3.32.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":2370,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.14283\/jpad.2018.17","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T08:24:05Z","timestamp":1614327845000},"page":"120-133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Literature Review of Methodologies Used in Randomized Clinical Trials of Agitation in Alzheimer's Disease"],"prefix":"10.1016","volume":"5","author":[{"given":"Sanjay","family":"Dub\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.T.","family":"Megerian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Malamut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.14283\/jpad.2018.17_bib1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jamda.2012.09.027","article-title":"The prevalence and course of neuropsychiatric symptoms in nursing home patients with dementia: a systematic review","volume":"14","author":"Selbaek","year":"2013","journal-title":"JJ Am Med Dir Assoc"},{"issue":"2","key":"10.14283\/jpad.2018.17_bib2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/gps.1858","article-title":"Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study","volume":"23","author":"Steinberg","year":"2008","journal-title":"Int J Geriatr Psychiatry"},{"issue":"6","key":"10.14283\/jpad.2018.17_bib3","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/JGP.0b013e3181faec23","article-title":"Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression study","volume":"19","author":"Tschanz","year":"2011","journal-title":"Am J Geriatr Psychiatry"},{"issue":"16","key":"10.14283\/jpad.2018.17_bib4","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1001\/jama.287.16.2090","article-title":"Patient and caregiver characteristics and nursing home placement in patients with dementia","volume":"287","author":"Yaffe","year":"2002","journal-title":"JAMA"},{"issue":"3","key":"10.14283\/jpad.2018.17_bib5","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1532-5415.2011.03314.x","article-title":"Neuropsychiatric symptoms and the risk of institutionalization and death: the aging, demographics, and memory study","volume":"59","author":"Okura","year":"2011","journal-title":"J Am Geriatr Soc"},{"issue":"12","key":"10.14283\/jpad.2018.17_bib6","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1017\/S1041610213001518","article-title":"The impact of neuropsychiatric symptoms on caregiver distress and quality of life in persons with dementia in an Asian tertiary hospital memory clinic","volume":"25","author":"Khoo","year":"2013","journal-title":"Int Psychogeriatr"},{"issue":"7","key":"10.14283\/jpad.2018.17_bib7","first-page":"P495","article-title":"Neuropsychiatric symptoms and their relationship with progression to severe dementia and death: findings of the MARACAIBO Aging Study (MAS)","volume":"12","author":"Castro","year":"2016","journal-title":"Alzheimers Dement"},{"issue":"11","key":"10.14283\/jpad.2018.17_bib8","doi-asserted-by":"crossref","first-page":"e013591","DOI":"10.1136\/bmjopen-2016-013591","article-title":"Predictors of care home and hospital admissions and their costs for older people with Alzheimer's disease: findings from a large London case register","volume":"6","author":"Knapp","year":"2016","journal-title":"BMJ Open"},{"key":"10.14283\/jpad.2018.17_bib9","unstructured":"US Food and Drug Administration. Division of Neuropharmacological Drug Products (DNDP) Issues Paper for March 9, 2000 Meeting of the Psychopharmacological Drugs Advisory Committee Meeting on the Various Psychiatric and Behavioral Disturbances Associated with Dementia. Silver Spring, MA; 2000. Contract No.: Doc PDAC\\AC030900.IP4."},{"issue":"1","key":"10.14283\/jpad.2018.17_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1017\/S1041610214001963","article-title":"Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition","volume":"27","author":"Cummings","year":"2015","journal-title":"Int Psychogeriatr"},{"issue":"6","key":"10.14283\/jpad.2018.17_bib11","doi-asserted-by":"crossref","first-page":"889","DOI":"10.4088\/JCP.v69n0602","article-title":"Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy","volume":"69","author":"Salzman","year":"2008","journal-title":"J Clin Psychiatry"},{"author":"US National Institutes of Health","key":"10.14283\/jpad.2018.17_bib12"},{"issue":"4","key":"10.14283\/jpad.2018.17_bib13","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jamda.2014.11.002","article-title":"A double-blind randomized placebocontrolled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD)","volume":"16","author":"Ballard","year":"2015","journal-title":"J Am Med Dir Assoc"},{"issue":"12","key":"10.14283\/jpad.2018.17_bib14","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1001\/jama.2015.10214","article-title":"Effect of dextromethorphanquinidine on agitation in patients with alzheimer disease dementia: a randomized clinical trial","volume":"314","author":"Cummings","year":"2015","journal-title":"JAMA"},{"issue":"23","key":"10.14283\/jpad.2018.17_bib15","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1212\/WNL.0000000000001675","article-title":"Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: a randomized controlled trial","volume":"84","author":"van den Elsen","year":"2015","journal-title":"Neurology"},{"issue":"7","key":"10.14283\/jpad.2018.17_bib16","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jama.2014.93","article-title":"Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial","volume":"311","author":"Porsteinsson","year":"2014","journal-title":"JAMA"},{"issue":"6","key":"10.14283\/jpad.2018.17_bib17","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1017\/S1041610213000239","article-title":"A randomized, doubleblind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease","volume":"25","author":"Herrmann","year":"2013","journal-title":"Int Psychogeriatr"},{"issue":"5","key":"10.14283\/jpad.2018.17_bib18","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1017\/S1041610212002141","article-title":"Mibampator (LY451395) randomized clinical trial for agitation\/aggression in Alzheimer's disease","volume":"25","author":"Trzepacz","year":"2013","journal-title":"Int Psychogeriatr"},{"issue":"5","key":"10.14283\/jpad.2018.17_bib19","doi-asserted-by":"crossref","first-page":"e35185","DOI":"10.1371\/journal.pone.0035185","article-title":"Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial","volume":"7","author":"Fox","year":"2012","journal-title":"PLoS One"},{"issue":"9","key":"10.14283\/jpad.2018.17_bib20","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1017\/S1041610211000743","article-title":"Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study","volume":"23","author":"Barak","year":"2011","journal-title":"Int Psychogeriatr"},{"issue":"1","key":"10.14283\/jpad.2018.17_bib21","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/JCP.0b013e3181ca0c59","article-title":"Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: a double-blind, randomized clinical trial","volume":"30","author":"Mowla","year":"2010","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"10.14283\/jpad.2018.17_bib22","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/JGP.0b013e318187de18","article-title":"Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease","volume":"17","author":"Gehrman","year":"2009","journal-title":"Am J Geriatr Psychiatry"},{"issue":"2","key":"10.14283\/jpad.2018.17_bib23","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000199236","article-title":"Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia","volume":"27","author":"Sommer","year":"2009","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"9","key":"10.14283\/jpad.2018.17_bib24","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1097\/JGP.0b013e3181ab8c61","article-title":"Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression","volume":"17","author":"Wang","year":"2009","journal-title":"Am JJ Geriatr Psychiatry"},{"issue":"7","key":"10.14283\/jpad.2018.17_bib25","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/JGP.0b013e318165db77","article-title":"A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease","volume":"16","author":"Streim","year":"2008","journal-title":"Am J Geriatr Psychiatry"},{"issue":"14","key":"10.14283\/jpad.2018.17_bib26","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa066583","article-title":"Donepezil for the treatment of agitation in Alzheimer's disease","volume":"357","author":"Howard","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"10.14283\/jpad.2018.17_bib27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.archger.2006.07.006","article-title":"Effects of rivastigmine on actigraphically monitored motor activity in severe agitation related to Alzheimer's disease: a placebo-controlled pilot study","volume":"45","author":"Mahlberg","year":"2007","journal-title":"Arch Gerontol Geriatr"},{"issue":"3","key":"10.14283\/jpad.2018.17_bib28","doi-asserted-by":"crossref","first-page":"341","DOI":"10.4088\/JCP.v69n0302","article-title":"Memantine for agitation\/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies","volume":"69","author":"Wilcock","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"16","key":"10.14283\/jpad.2018.17_bib29","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1056\/NEJMoa1114058","article-title":"Relapse risk after discontinuation of risperidone in Alzheimer's disease","volume":"367","author":"Devanand","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"10.14283\/jpad.2018.17_bib30","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/archgenpsychiatry.2011.72","article-title":"Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease","volume":"68","author":"Tariot","year":"2011","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"10.14283\/jpad.2018.17_bib31","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jalz.2011.01.007","article-title":"Citalopram for agitation in Alzheimer's disease: design and methods","volume":"8","author":"Drye","year":"2012","journal-title":"Alzheimers Dement"},{"issue":"7","key":"10.14283\/jpad.2018.17_bib32","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"issue":"3","key":"10.14283\/jpad.2018.17_bib33","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"year":"2013","series-title":"Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5\u00ae)","author":"American Psychiatric Association","key":"10.14283\/jpad.2018.17_bib34"},{"issue":"3","key":"10.14283\/jpad.2018.17_bib35","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u00abMini-mental state\u00bb. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"issue":"6","key":"10.14283\/jpad.2018.17_bib36","first-page":"S10","article-title":"The Neuropsychiatric Inventory: assessing psychopathology in dementia patients","volume":"48","author":"Cummings","year":"1997","journal-title":"Neurology"},{"journal-title":"Instruction Manual for the Cohen-Mansfield Agitaion Inventory (CMAI)","year":"1991","author":"Cohen-Mansfield","key":"10.14283\/jpad.2018.17_bib37"},{"key":"10.14283\/jpad.2018.17_bib38","series-title":"ECDEU Assessment Manual For Psychopharmacology","article-title":"Abnormal involuntary movement scale","author":"Guy","year":"1976"},{"issue":"3","key":"10.14283\/jpad.2018.17_bib39","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/WAD.0b013e31819cb760","article-title":"Characteristics and performance of a modified version of the ADCS-CGIC CIBIC+ for mild cognitive impairment clinical trials","volume":"23","author":"Schneider","year":"2009","journal-title":"Alzheimer Disease and Associated Disorders"},{"issue":"6","key":"10.14283\/jpad.2018.17_bib40","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1532-5415.1992.tb02101.x","article-title":"Assessment of cognitive, psychiatric, and behavioral disturbances in patients with dementia: the Neurobehavioral Rating Scale","volume":"40","author":"Sultzer","year":"1992","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"10.14283\/jpad.2018.17_bib41","first-page":"301","article-title":"Behavioral pathology in Alzheimer's disease (BEHAVE-AD) rating scale","volume":"8","author":"Reisberg","year":"1996","journal-title":"Int Psychogeriatr"},{"issue":"1","key":"10.14283\/jpad.2018.17_bib42","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/00019442-199400210-00008","article-title":"A user-friendly instrument for rating agitation in dementia patients","volume":"2","author":"Rosen","year":"1994","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.14283\/jpad.2018.17_bib43","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol Rep"},{"issue":"1","key":"10.14283\/jpad.2018.17_bib44","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1532-5415.1993.tb05948.x","article-title":"A brief agitation rating scale (BARS) for nursing home elderly","volume":"41","author":"Finkel","year":"1993","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"10.14283\/jpad.2018.17_bib45","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1037\/0882-7974.7.4.622","article-title":"Assessment of behavioral problems in dementia: the revised memory and behavior problems checklist","volume":"7","author":"Teri","year":"1992","journal-title":"Psychol Aging"},{"key":"10.14283\/jpad.2018.17_bib46","first-page":"1","article-title":"Medication development for agitation and aggression in Alzheimer disease: review and discussion of recent randomized clinical trial design","author":"Soto","year":"2014","journal-title":"Int Psychogeriatr"},{"issue":"12","key":"10.14283\/jpad.2018.17_bib47","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1017\/S1041610215001106","article-title":"Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial","volume":"27","author":"Rosenberg","year":"2015","journal-title":"Int Psychogeriatr"},{"key":"10.14283\/jpad.2018.17_bib48","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1471-2288-11-90","article-title":"Novel study designs to investigate the placebo response","volume":"11","author":"Enck","year":"2011","journal-title":"BMC Med Res Methodol"},{"issue":"11","key":"10.14283\/jpad.2018.17_bib49","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.jagp.2015.05.006","article-title":"Time to response to citalopram treatment for agitation in Alzheimer disease","volume":"23","author":"Weintraub","year":"2015","journal-title":"Am J Geriatr Psychiatry"},{"issue":"5","key":"10.14283\/jpad.2018.17_bib50","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1176\/appi.ajp.2015.15050648","article-title":"Heterogeneity of treatment response to citalopram for patients with Alzheimer's disease with aggression or agitation: the CitAD randomized clinical trial","volume":"173","author":"Schneider","year":"2016","journal-title":"Am J Psychiatry"},{"issue":"5","key":"10.14283\/jpad.2018.17_bib51","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1176\/appi.ajp.2016.15020248","article-title":"Effects of citalopram on neuropsychiatric symptoms in Alzheimer's dementia: evidence from the CitAD Study","volume":"173","author":"Leonpacher","year":"2016","journal-title":"Am J Psychiatry"},{"issue":"8","key":"10.14283\/jpad.2018.17_bib52","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archneurol.2011.69","article-title":"Lack of evidence for the efficacy of memantine in mild Alzheimer disease","volume":"68","author":"Schneider","year":"2011","journal-title":"Arch Neurol"},{"year":"2015","series-title":"Transition Therapeutics announces results of clinical study of ELND005 in agitation and aggression in patients with Alzheimer's disease [press release]","key":"10.14283\/jpad.2018.17_bib53"},{"year":"2015","series-title":"Transition Therapeutics announces results of data analysis from ELND005 phase 2\/3 clinical study in agitation and aggression in Alzheimer's disease Patients [press release]","key":"10.14283\/jpad.2018.17_bib54"},{"issue":"4","key":"10.14283\/jpad.2018.17_bib55","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/alzrt48","article-title":"Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice","volume":"2","author":"Robert","year":"2010","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"10.14283\/jpad.2018.17_bib56","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/jgs.12730","article-title":"Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel","volume":"62","author":"Kales","year":"2014","journal-title":"J Am Geriatr Soc"},{"key":"10.14283\/jpad.2018.17_bib57","first-page":"63","article-title":"Effect of sample size re-estimation in adaptive clinical trials for Alzheimer's disease and mild cognitive impairment","volume":"1","author":"Wang","year":"2015","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.14283\/jpad.2018.17_bib58","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4103\/0253-7613.68417","article-title":"Adaptive design clinical trials: methodology, challenges and prospect","volume":"42","author":"Mahajan","year":"2010","journal-title":"Indian J Pharmacol"},{"author":"US Department of Health and Human Services","key":"10.14283\/jpad.2018.17_bib59"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724005703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724005703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T02:41:56Z","timestamp":1736476916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724005703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S2274580724005703"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2018.17","relation":{},"ISSN":["2274-5807"],"issn-type":[{"type":"print","value":"2274-5807"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Literature Review of Methodologies Used in Randomized Clinical Trials of Agitation in Alzheimer's Disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2018.17","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}